Fig. 3.
Role of CD8+ T cells during rMVA-CD40L-induced tumor growth control. a, b CD8 depletion in B16.OVA tumor-bearing mice. When B16.OVA tumors were above 50 mm3, mice received PBS or were immunized with 5 × 107 TCID50 of either rMVA or rMVA-CD40L. Where indicated, mice received at days −2, 2, 6, and 10 after immunization 200 µg of either IgG2b or anti-CD8 antibody i.p. a Tumor size follow-up (n = 5 mice/group) and b overall survival. a Representative growth of PBS and rMVA-CD40L-treated groups in at least two independent experiments. b Represents overall survival of one independent experiment. Data in a expressed as mean ± SEM. c–f C57BL/6 mice bearing 50 mm3 B16.OVA tumors (n = 5 mice/group) received PBS or were immunized with 5 × 107 TCID50 of either rMVA, rMVA-CD40L, or rMVA-Profilin. c Quantitative expression of IL12p70 and IFN-γ in sera 6 h after systemic immunization. d Percentage of CD44+OVA257-264-specific CD8+ T cells among peripheral blood leukocytes (PBL) 7 days after immunization. e Tumor size follow-up. f Overall survival. c–e Data representative of two independent experiments. f Survival of two merged independent experiments. Data in a, c, d, and e are expressed as mean ± SEM. One-way ANOVA was performed on figures a, c, d, and e. Log-rank test on mouse survival was performed for b and f. NS, nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.005